Can-Fite BioPharma Ltd.
CANF- Exchange
- NYSE
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001536196
No open-market purchases or sales by Can-Fite BioPharma Ltd. insiders were filed in the last 90 days; 8 institutions reported holding it in 13F filings for Q2 2026, worth $149.1K in total; no superinvestor holds it.
Q2 2025 vs. Q1 2025
How the institutions holding Can-Fite BioPharma Ltd. changed between Q1 2025 and Q2 2025.
All holders in Q2 2025All holders in Q1 2025
| Measure | Q1 2025 | Q2 2025 | Change |
|---|---|---|---|
| Holders | 14 | 16 | +2 |
| Shares | 131.3K | 905.0K | +773.7K (+589.1%) |
| Value | $193.9K | $950.1K | +$756.2K (+390.1%) |
New holders (5)
Institutions that held Can-Fite BioPharma Ltd. at the end of Q2 2025 but not at the end of Q1 2025.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Sabby Management, LLC | 779,744 | $818.7K | 6.30% |
| Two Sigma Securities, LLC | 16,064 | $16.9K | 0.00% |
| UBS Group AG | 5,515 | $5.79K | 0.00% |
| Advisor Group Holdings, Inc. | 180 | $189 | 0.00% |
| Bank of America Corp | 6 | $6 | 0.00% |
Sold out (3)
Institutions that held Can-Fite BioPharma Ltd. at the end of Q1 2025 and filed for Q2 2025 without it.
| Institution | Shares, Q1 2025 | Value, Q1 2025 |
|---|---|---|
| XTX Topco Ltd | 15,271 | $22.6K |
| Virtu Financial LLC | 13,740 | $20.0K |
| National Bank of Canada | 600 | $888 |